Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

OSE Immunotherapeutics - Filing #831399

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	51 576 EUR	—	—	—	54 581 EUR	—	—	—	—	—	—
Current assets	—	—	—	30 478 EUR	—	—	—	37 200 EUR	—	—	—	—	—	—
Non-current liabilities	—	—	—	40 280 EUR	—	—	—	42 856 EUR	—	—	—	—	—	—
Current liabilities	—	—	—	18 799 EUR	—	—	—	16 268 EUR	—	—	—	—	—	—
Revenue	—	2 227 EUR	—	—	—	—	—	—	—	—	18 302 EUR	—	—	—
Profit (loss)	—	23 003 EUR	—	—	—	23 003 EUR	—	—	—	—	17 760 EUR	—	—	17 760 EUR
Other comprehensive income	—	86,000 EUR	—	—	—	—	—	—	—	—	61,000 EUR	—	—	—
Comprehensive income	0 EUR	23 089 EUR	0 EUR	—	0 EUR	23 012 EUR	77,000 EUR	—	0 EUR	0 EUR	17 699 EUR	0 EUR	61,000 EUR	17 638 EUR